Antibody Drug Conjugates Contract Manufacturing Market Size, Share & Trends Analysis Report By Linker (Cleavable, Non-cleavable), By Condition (Myeloma, Lymphoma, Breast Cancer), By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends
The global antibody drug conjugates contract manufacturing market size is expected t%li%reach USD 16.55 billion by 2030, registering a CAGR of 10.99% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing t%li%the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing t%li%the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.
The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected t%li%rise even further owing t%li%the growing prevalence of cancer worldwide. This is expected t%li%support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.
For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding t%li%build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected t%li%improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected t%li%boost the demand for contract manufacturing services for ADC.
Antibody Drug Conjugates Contract Manufacturing Market Report Highlights
Antibody Drug Conjugates Contract Manufacturing Market Growth & Trends
The global antibody drug conjugates contract manufacturing market size is expected t%li%reach USD 16.55 billion by 2030, registering a CAGR of 10.99% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The factors driving the industry growth include the complex nature of antibody drug conjugates (ADCs) contributing t%li%the demand for contract manufacturing, the increasing number of research on antibody therapies, and the rise in cancer incidence. During the pandemic, the clinical trials for cancer were stopped for a short period. However, owing t%li%the severity of the disease, the trials were started again. As per the IQVIA Oncology Trends Report 2022, the number of clinical trials for cancer is growing.
The IQVIA report states that there was a 56% increase in oncology clinical trials between 2016 and 2021. This number of clinical studies is expected t%li%rise even further owing t%li%the growing prevalence of cancer worldwide. This is expected t%li%support the ADC development and manufacturing activities, thus supporting industry growth post-pandemic. Antibody drug conjugates have high efficiency in treating cancer as it only targets the cancerous cells and does not affect the healthy cells of the body. As a result, several biopharmaceutical companies have received significant funding for ADC-related research.
For instance, in October 2022, Mablink Bioscience, raise USD 31 million from Series A funding t%li%build its antibody drug conjugate pipeline. Thus, heavy investments in the R&D of ADCs are expected t%li%improve their availability in the coming years and thus support the demand for ADC contract manufacturing. In September 2021, the U.S. FDA provided accelerated approval for ADC tisotumab vedotin-tftv for treating adult patients with recurrent or metastatic cervical cancer with disease progression or after chemotherapy. Such approvals, in the coming years, are expected t%li%boost the demand for contract manufacturing services for ADC.
Antibody Drug Conjugates Contract Manufacturing Market Report Highlights
- Based on condition, the market includes myeloma, lymphoma, breast cancer and others. The myeloma segment led the market with the largest revenue share of 49.61% in 2024. The lymphoma segment is anticipated t%li%witness the fastest CAGR during the forecast period.
- Based on linker, the market is segmented int%li%cleavable linkers and non-cleavable linkers. The cleavable linkers segment led the market with the largest revenue share of 56.1% in 2024.
- The antibody drug conjugates contract manufacturing market in North America is expected t%li%witness the fastest CAGR over the forecast period.
- Asia Pacific antibody drug conjugates contract manufacturing market dominated the market with the largest revenue share of 40.93% in 2024. The regional growth is primarily owing t%li%supportive regulatory reforms, especially in countries such as India & China, and low-cost labor.
CHAPTER 1. RESEARCH METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates And Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
1.10.1. Objective-1
1.10.2. Objective-2
1.10.3. Objective-3
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Incidence of Cancer
3.2.1.2. High Cost of Manufacturing ADC and Challenges Associated With Manufacturing Contributing to the Demand for Contract Manufacturing
3.2.1.3. Increasing R&D Activities on ADCs
3.2.2. Market Restraint Analysis
3.2.2.1. Quality Issues While Outsourcing
3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Industry Ecosystem Analysis
3.6. Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
CHAPTER 4. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET: CONDITION ESTIMATES & TREND ANALYSIS
4.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Segment Dashboard
4.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Movement Analysis
4.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Condition, 2018 - 2030 (USD Million)
4.4. Myeloma
4.4.1. Myeloma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Lymphoma
4.5.1. Lymphoma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Breast Cancer
4.6.1. Breast Cancer Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET: LINKER ESTIMATES & TREND ANALYSIS
5.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Segment Dashboard
5.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Movement Analysis
5.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Linker, 2018 - 2030 (USD Million)
5.4. Cleavable Linker
5.4.1. Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Non-Cleavable Linker
5.5.1. Non-Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. North America
6.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
6.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework
6.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Competitive Scenario
6.5.9.3. Regulatory Framework
6.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework
6.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Australia
6.6.7.1. Key Country Dynamics
6.6.7.2. Competitive Scenario
6.6.7.3. Regulatory Framework
6.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. MEA
6.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework
6.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework
6.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework
6.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Competitive Scenario
6.8.5.3. Regulatory Framework
6.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2024
7.3. Company Profiles
7.3.1. Sterling
7.3.1.1. Company Overview
7.3.1.2. Financial Performance
7.3.1.3. Service Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Recipharm AB
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Service Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Lonza
7.3.3.1. Company Overview
7.3.3.2. Financial Performance
7.3.3.3. Service Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Catalent, Inc.
7.3.4.1. Company Overview
7.3.4.2. Financial Performance
7.3.4.3. Service Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Sartorius AG
7.3.5.1. Company Overview
7.3.5.2. Financial Performance
7.3.5.3. Service Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Wuxi Biologics
7.3.6.1. Company Overview
7.3.6.2. Financial Performance
7.3.6.3. Service Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Samsung Biologics
7.3.7.1. Company Overview
7.3.7.2. Financial Performance
7.3.7.3. Service Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Piramal Group (Piramal Pharma Solutions)
7.3.8.1. Company Overview
7.3.8.2. Financial Performance
7.3.8.3. Service Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
7.3.9.1. Company Overview
7.3.9.2. Financial Performance
7.3.9.3. Service Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Merck KGaA
7.3.10.1. Company Overview
7.3.10.2. Financial Performance
7.3.10.3. Service Benchmarking
7.3.10.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates And Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Parent Market Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
1.10.1. Objective-1
1.10.2. Objective-2
1.10.3. Objective-3
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Incidence of Cancer
3.2.1.2. High Cost of Manufacturing ADC and Challenges Associated With Manufacturing Contributing to the Demand for Contract Manufacturing
3.2.1.3. Increasing R&D Activities on ADCs
3.2.2. Market Restraint Analysis
3.2.2.1. Quality Issues While Outsourcing
3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
3.3. Technology Landscape
3.4. Pricing Model Analysis
3.5. Industry Ecosystem Analysis
3.6. Market Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.6.3. COVID-19 Impact Analysis
CHAPTER 4. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET: CONDITION ESTIMATES & TREND ANALYSIS
4.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Segment Dashboard
4.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Condition: Movement Analysis
4.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Condition, 2018 - 2030 (USD Million)
4.4. Myeloma
4.4.1. Myeloma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.5. Lymphoma
4.5.1. Lymphoma Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.6. Breast Cancer
4.6.1. Breast Cancer Market Estimates and Forecasts, 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Others Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 5. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET: LINKER ESTIMATES & TREND ANALYSIS
5.1. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Segment Dashboard
5.2. Antibody Drug Conjugates (ADC) Contract Manufacturing Market, By Linker: Movement Analysis
5.3. Antibody Drug Conjugates (ADC) Contract Manufacturing Market Estimates & Forecasts, By Linker, 2018 - 2030 (USD Million)
5.4. Cleavable Linker
5.4.1. Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
5.5. Non-Cleavable Linker
5.5.1. Non-Cleavable Linker Market Estimates and Forecasts, 2018 to 2030 (USD Million)
CHAPTER 6. ANTIBODY DRUG CONJUGATES (ADC) CONTRACT MANUFACTURING MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Market Share Analysis, 2024 & 2030
6.2. Regional Market Dashboard
6.3. Global Regional Market Snapshot
6.4. North America
6.4.1. North America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Europe
6.5.1. Europe Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework
6.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Competitive Scenario
6.5.9.3. Regulatory Framework
6.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Competitive Scenario
6.6.4.3. Regulatory Framework
6.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. Thailand
6.6.5.1. Key Country Dynamics
6.6.5.2. Competitive Scenario
6.6.5.3. Regulatory Framework
6.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Competitive Scenario
6.6.6.3. Regulatory Framework
6.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Australia
6.6.7.1. Key Country Dynamics
6.6.7.2. Competitive Scenario
6.6.7.3. Regulatory Framework
6.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. MEA
6.8.1. MEA Market Estimates and Forecasts, 2018 to 2030 (Revenue, USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Competitive Scenario
6.8.2.3. Regulatory Framework
6.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Competitive Scenario
6.8.3.3. Regulatory Framework
6.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Competitive Scenario
6.8.4.3. Regulatory Framework
6.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Competitive Scenario
6.8.5.3. Regulatory Framework
6.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Company Market Share/Assessment Analysis, 2024
7.3. Company Profiles
7.3.1. Sterling
7.3.1.1. Company Overview
7.3.1.2. Financial Performance
7.3.1.3. Service Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Recipharm AB
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Service Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Lonza
7.3.3.1. Company Overview
7.3.3.2. Financial Performance
7.3.3.3. Service Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Catalent, Inc.
7.3.4.1. Company Overview
7.3.4.2. Financial Performance
7.3.4.3. Service Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Sartorius AG
7.3.5.1. Company Overview
7.3.5.2. Financial Performance
7.3.5.3. Service Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Wuxi Biologics
7.3.6.1. Company Overview
7.3.6.2. Financial Performance
7.3.6.3. Service Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Samsung Biologics
7.3.7.1. Company Overview
7.3.7.2. Financial Performance
7.3.7.3. Service Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Piramal Group (Piramal Pharma Solutions)
7.3.8.1. Company Overview
7.3.8.2. Financial Performance
7.3.8.3. Service Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. AbbVie, Inc. (AbbVie Contract Manufacturing)
7.3.9.1. Company Overview
7.3.9.2. Financial Performance
7.3.9.3. Service Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Merck KGaA
7.3.10.1. Company Overview
7.3.10.2. Financial Performance
7.3.10.3. Service Benchmarking
7.3.10.4. Strategic Initiatives
